Inflammatory Index as a Predictor for Endometrial Cancer: an Observational Study
Launched by UNIVERSITY OF CAMPANIA LUIGI VANVITELLI · Dec 10, 2022
Trial Information
Current as of January 16, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying how certain markers of inflammation in the body might help predict the risk of endometrial cancer in women. Inflammation can be measured in different ways, and this trial specifically looks at three ratios: the neutrophil-to-lymphocyte ratio (NLR), the platelet-to-lymphocyte ratio (PLR), and the lymphocyte-to-monocyte ratio (MRL). The goal is to see if changes in these ratios can help classify the risk of patients according to existing guidelines in Europe.
Women aged 18 and older who have been diagnosed with endometrial cancer and are planning to have surgery may be eligible to participate. Participants will be asked to give their consent to join the study and will receive a full-body CT scan within 30 days before joining. It's important to note that those with certain chronic inflammatory diseases, recent cancer diagnoses, or those on steroid therapy might not be able to participate. If you choose to take part, you'll help researchers better understand the connection between inflammation and endometrial cancer, which could lead to improved care for future patients.
Gender
FEMALE
Eligibility criteria
- Inclusion Criteria:
- • Patients histologically diagnosed with endometrial cancer.
- • Patients undergoing surgical staging of the disease.
- • Patients undergoing full-body CT-scan 30 days before enrollment.
- • At least 18-year-old patients.
- Exclusion Criteria:
- • Unfit to plead.
- • Patients with chronic inflammatory diseases (IBDs; rheumatic conditions).
- • Synchronous tumors or cancer diagnosis in the previous 3 years.
- • Patients undergoing steroid therapy in the last 30 days prior to recruitment
Trial Officials
Carlo Ronsini, MD
Principal Investigator
University of Campania Luigi Vanvitelli
About University Of Campania Luigi Vanvitelli
The University of Campania Luigi Vanvitelli is a distinguished academic institution located in Italy, renowned for its commitment to advancing medical research and improving healthcare outcomes. As a clinical trial sponsor, the university leverages its extensive expertise in biomedical sciences to conduct innovative studies that address critical health challenges. With a focus on ethical standards and patient safety, the university collaborates with various healthcare professionals and research entities to facilitate groundbreaking clinical investigations, ultimately contributing to the development of new therapies and enhancing medical knowledge.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Naples, , Italy
People applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Discussion 0
Similar Trials